Sichenzia Ross Ference Kesner LLP Represents Laidlaw & Company (UK) Ltd. in $5.2 Million Public Offering
Press Release – New York, NY – May 8, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Laidlaw & Company (UK) Ltd. as sole book-running manager in the underwritten public offering of equity securities of Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). In connection with the offering, Onconova received approximately $5.2 million in gross proceeds from common stock sold at a price to the public of $2.10 per share.
The Sichenzia Ross Ference Kesner LLP team was led by Partners Harvey Kesner and Avital Perlman and associate Evan Berger.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- 加州新商业融资披露立法 - September 28, 2018
- Sichenzia Ross Ference LLP宣布推出新的Web域名 - September 26, 2018
- Sichenzia Ross Ference LLP Represents AIT Therapeutics, Inc. in $20,000,000 Line of Credit - September 6, 2018